Drug delivery is a multidisciplinary field. Researchers recently developed a drug-delivery system to mitigate some problems
associated with jet-injection drug delivery, and also improved on the design and operation of microscale actuators as a possible
Researchers at the Massachusetts Institute of Technology (MIT) recently developed a jet-injection drug-delivery system based
on a custom high-stroke Lorentz-force motor to mitigate some of the problems typically associated with controlling drug delivery
through jet injection. The researchers noted that needle-free drug delivery by jet injection typically is achieved by ejecting
a liquid drug through a narrow orifice at high pressure, thereby creating a fine high-speed fluid jet that can readily penetrate
skin and tissue. The researchers assert that such injection systems use force- and pressure-generating principles that cause
injection in an uncontrolled manner with limited ability to regulate delivery volume and injection depth. To address these
shortcomings, the researchers developed a controllable jet injection device, based on a custom high-stroke linear Lorentz-force
motor that is feed-back controlled during the time-course of an injection (1).
The key part of the design is the Lorentz-force actuator, a magnet surrounded by a coil of wire that is attached to a piston
inside a drug ampul, according to a May 24, 2012 MIT press release. When a current is applied, it interacts with the magnetic
field to produce a force that pushes the piston forward, ejecting the drug at very high pressure and velocity out through
the ampul’s nozzle. The speed of the coil and the velocity can be controlled by the amount of current applied. The resulting
waveforms generally consist of two distinct phases: an initial high-pressure phase in which the device ejects drug at a high-enough
velocity to breach the skin and reach the desired depth, then a lower-pressure phase where drug is delivered in a slower stream
that can easily be absorbed by the surrounding tissue, according to the MIT press release. Through testing, the group found
that various skin types may require different waveforms to deliver adequate volumes of drugs to the desired depth (1).
The team is also developing a version of the device for transdermal delivery of drugs ordinarily found in powdered form by
programming the device to vibrate, turning powder into a fluidized form that can be delivered through the skin much like a
liquid, according to MIT release. Such a powder-delivery vehicle may help mitigate the problems associated with needing a
cold-chain system for delivering vaccines and other biopharmaceuticals.
In another development, researchers at the US Department of Energy (DOE)’s Lawrence Berkeley National Laboratory (Berkeley
Lab) and the University of California, Berkeley, have developed an new microscale actuator based on an vanadium dioxide that
expands and contracts in response to a small temperature variation and which show promise for drug delivery among other applications.
Piezoelectric actuators are the industry-standard for mechanical actuation on micro scales, but they are complicated to grow,
need large voltages for small displacements, and typically involve toxic materials such as lead, according to a Dec. 2012
Berkeley Lab press release. The researchers’ device is simpler, uses nontoxic materials, and creates a displacement that is
larger at a lower driving voltage. It works equally well in water, making it suitable for biological and microfluidic applications.
The researchers envision using the microactuators as tiny pumps for drug delivery (2) .
1. A. Taberner, N.C. Hogan, and I.W. Hunter, Medical Eng. & Physics, online, DOI/10.1016/j.medengphy.2011.12.010, Jan. 13, 2012.
2. J. Wu, Nano Lett., 12 (12), 6302-6308 (2012).